Back to School: How biopharma can reboot drug development. Access exclusive analysis here
NBIX fell $5 (49%) to $5.25 on Thursday after receiving a second FDA approvable letter for indiplon 5
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury